Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
physostigmine + scopolamine
- Development stage
- Preclinical
- Lead developer
- UK Armed Forces
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
A combination of physostigmine and scopolamine that has been studied primarily as a protective treatment against nerve agent toxicity. Physostigmine is a cholinesterase inhibitor that crosses the blood-brain barrier, while scopolamine is an anticholinergic agent. This combination has demonstrated protection against the lethal and behavioral effects of nerve agents such as soman and sarin.
02
Targets
AcetylcholinesterasemAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on physostigmine + scopolamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on physostigmine + scopolamine.